Syros Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:0S90 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
02 Dec 24	Sell€9,545	Nancy Simonian	Individual	37,070	€0.26
25 Nov 24	Sell€34,092	Nancy Simonian	Individual	134,713	€0.25
19 Nov 24	Sell€9,747	Gerald Quirk	Individual	46,657	€0.21
18 Nov 24	Sell€27,418	Jason Haas	Individual	137,803	€0.20
18 Nov 24	Sell€2,254	David Roth	Individual	12,099	€0.19
18 Nov 24	Sell€7,521	Kristin Stephens	Individual	36,133	€0.21
18 Nov 24	Sell€25,481	Conley Chee	Individual	134,797	€0.19
12 Sep 24	Buy€146,115	Jason Haas	Individual	100,000	€1.52
11 Sep 24	Buy€145,930	Conley Chee	Individual	100,000	€1.55

Insider Trading Volume

Insider Buying: 0S90 insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of 0S90?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	165,007	0.615%
General Public	5,157,742	19.2%
Hedge Funds	6,401,853	23.9%
VC/PE Firms	7,123,950	26.5%
Institutions	7,983,905	29.8%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.2%.

Top Shareholders

Top 25 shareholders own 77.64% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
10.7%	Avidity Partners Management, L.P.	2,857,573	€557.7k	70.8%	0.03%
10.3%	Bain Capital Life Sciences Investors, LLC	2,750,151	€536.7k	0.01%	0.06%
9.64%	Artal Group S.A.	2,587,372	€505.0k	3.29%	0.02%
7.72%	Adage Capital Management, L.P.	2,071,914	€404.4k	0%	no data
6.66%	Samsara BioCapital LLC	1,786,427	€348.7k	0%	0.05%
5.49%	Point72 Asset Management, L.P.	1,472,366	€287.4k	-0.22%	no data
4.82%	Flagship Pioneering, Inc	1,293,849	€252.5k	0%	0.08%
3.55%	The Vanguard Group, Inc.	953,313	€186.1k	-1.54%	no data
3.09%	Deep Track Capital, LP	828,485	€161.7k	0%	0.01%
2.44%	Opaleye Management Inc.	654,943	€127.8k	-24.3%	0.02%
1.98%	Cowen Inc,Private Banking and Investment Banking Investments	531,914	€103.8k	0%	no data
1.92%	CHI Advisors LLC	515,855	€100.7k	51.3%	0.05%
1.34%	UBS O'Connor LLC	359,305	€70.1k	29.2%	0.01%
1.17%	ExodusPoint Capital Management, LP	313,004	€61.1k	18.7%	no data
1.11%	Exome Asset Management LLC	298,575	€58.3k	87.6%	0.04%
0.97%	BlackRock, Inc.	261,579	€51.1k	0.92%	no data
0.94%	Omega Fund Management, LLC	251,270	€49.0k	0%	0.03%
0.8%	Invus Financial Advisors, LLC	214,159	€41.8k	0%	0.04%
0.76%	Geode Capital Management, LLC	204,695	€40.0k	-9.47%	no data
0.6%	Marshall Wace LLP	160,390	€31.3k	0%	no data
0.44%	Perceptive Advisors LLC	116,754	€22.8k	0%	no data
0.36%	Renaissance Technologies LLC	96,435	€18.8k	-17.9%	no data
0.33%	Prelude Capital Management, LLC	89,097	€17.4k	121%	no data
0.32%	Walleye Capital LLC	86,641	€16.9k	-69.7%	no data
0.29%	Qube Research & Technologies Ltd	77,716	€15.2k	176%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/25 15:41
End of Day Share Price	2024/12/23 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Syros Pharmaceuticals, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Leah Rush Cann	Brookline Capital Markets
Andrew Fein	H.C. Wainwright & Co.
Jason Butler	JMP Securities